Amphastar Pharmaceuticals
AMPH
245 hedge funds and large institutions have $752M invested in Amphastar Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 91 increasing their positions, 73 reducing their positions, and 40 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 73
17% more call options, than puts
Call options by funds: $447K | Put options by funds: $381K
13% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 40
2% more funds holding
Funds holding: 241 → 245 (+4)
0.35% less ownership
Funds ownership: 69.75% → 69.41% (-0.35%)
22% less capital invested
Capital invested by funds: $964M → $752M (-$212M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7.26M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.71M |
| 3 |
D.E. Shaw & Co
New York
|
+$6.57M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.55M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.2M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$11.9M |
| 3 |
BlackRock
New York
|
-$11.9M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$10.9M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$7.71M |
AMPH Hedge Fund Activity: Q2 2025 in Review
245 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2025, worth a combined $752M — down 22% from $964M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new AMPH positions and 40 closed out — a net gain of 5 holders — while 91 added to existing stakes and 73 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $7.26M. The largest seller was Federated Hermes, cutting an estimated $14.2M.
- 245 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2025, up from 241 in Q1 2025.
- Funds reported $752M of Amphastar Pharmaceuticals stock for Q2 2025, down 22% quarter-over-quarter.
- 45 funds opened new Amphastar Pharmaceuticals positions in Q2 2025 and 40 closed out, a net change of +5 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2025 was Royal Bank of Canada, an estimated $7.26M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2025 was Federated Hermes, an estimated $14.2M sold.
Based on aggregated 13F filings for Q2 2025.